**Dear Editor**,

c-Myc is highly associated with poor prognosis and aggressive progression of diffuse large B cell lymphoma (DLBCL) and is thus a desirable drug target. Moreover, studies indicate that 5--15% of DLBCL patients harbor MYC and BCL-2 translocations, while 20--35% DLBCL patients simultaneously overexpress of c-Myc and BCL-2 proteins without gene rearrangements.^[@CR1]^ These two types of DLBCL are referred as "double-hit" lymphoma (DHL) and "double-expressor" lymphoma (DEL), respectively. Both DHL and DEL lymphomas have inferior clinical outcomes and are refractory to R-CHOP or even hematopoietic stem cell transplant.^[@CR2]^ Thus, targeting both c-Myc and BCL-2 is a promising strategy to treat high-risk DLBCLs.^[@CR3]^ Although BCL-2 inhibitors are clinically available, c-Myc remains to be "undruggable" owing to its lack of kinase activity and intrinsically disordered structure.^[@CR4]^ Thus, developing clinically applicable c-Myc inhibitor remains challenging.

YL064 is a novel sinomenine derivative (Supplementary Fig. [S1a, b](#MOESM1){ref-type="media"}) identified in our previous study that inhibits cell growth by targeting STAT3 in multiple myeloma.^[@CR5]^ However, the effect of YL064 on DLBCL has never been investigated. In this study, we investigated the anti-lymphoma activity of YL064 in DLBCL. As shown in Fig. [1a](#Fig1){ref-type="fig"}, YL064 significantly reduced the viability of DLBCL cell lines. When we treated OCI-Ly3 and SU-DHL-2 cells with YL064 or sinomenine (0--10 μM) for 12, 24, and 48 h, YL064 but not sinomenine decreased cell viability in a dose- and time-dependent manner (Supplementary Fig. [S2a, b](#MOESM1){ref-type="media"}). We further evaluated the influence of YL064 on apoptosis induction and cell cycle progression in DLBCL cells. The treatment of OCI-Ly3 and SU-DHL-2 cells with YL064 significantly increased apoptosis, as evidenced by the increased Annexin V positive cells (Supplementary Fig. [S2c](#MOESM1){ref-type="media"}) and the substantially increased cleavage of caspase-3, −9 and PARP (Supplementary Fig. [S2d](#MOESM1){ref-type="media"}). Moreover, YL064 treatment for 24 h increased TUNEL-positive cells in OCI-Ly3 and SU-DHL-2 cells (Supplementary Fig. [S2e](#MOESM1){ref-type="media"}). Cell cycle analysis showed that YL064-induced G2/M-phase arrest at 12 h (Supplementary Fig. [S2f](#MOESM1){ref-type="media"}). These results demonstrate that YL064 exhibits anti-DLBCL effect by inducing cell apoptosis and G2/M-phase arrest.Fig. 1**a** DLBCL cell lines were treated with YL064 at different concentrations for 48 h, and the cell viability was assessed by CCK-8 assay. **b** Heatmap of the top 40 significantly downregulated genes for c-Myc targets in OCI-Ly3 cells treated with YL064 (10 μM) versus DMSO for 6 h. Rows show *Z*-scores are calculated. **c** OCI-Ly3 cells were treated with the indicated concentrations of YL064 for 12 h (left panel) or YL064 (10 μM) for the indicated time points (right panel). Protein expression was determined by western blotting. **d** OCI-Ly3 cells were treated with YL064 (10 μM) in the presence or absence of MG132 (5 μM, left panel) or chloroquine (20 μM, right panel) for 6 h, the indicated proteins were examined by western blotting. **e** The binding between YL064 and c-Myc protein in OCI-Ly3 cells was examined by the CETSA method at different temperatures (upper panel) or doses (lower panel). The protein levels were evaluated by western blotting. The intensity of the c-Myc bands was quantified by Image J software. **f** Biotin-YL064 (50 μM) binding to c-Myc from OCI-Ly3 cell lysate was analyzed after pre-treatment with YL064 (10×). **g** The recombinant c-Myc protein was incubated with biotin-YL064 or biotin for 30 min. The mixtures were subjected to western blotting against biotin or c-Myc. **h** After treatment with or without 10 μM biotin-YL064 for 6 h, OCI-Ly3 cells were stained with c-Myc antibody (c-Myc; red) and streptavidin-FITC (green), followed by counterstaining with DAPI. Scale bars, 10 μm. **i** OCI-Ly3 cells were treated with the indicated concentrations of YL064 and ABT-199, alone and in combination for 48 h. Combination index (CI) for each combination were calculated with the data obtained from the CCK-8 assays with the Calcusyn program. **j**--**m** OCI-Ly3 cells were xenografted in mice as described in supplementary Materials and methods. Mice were treated with vehicle, 30 mg/kg YL064, 50 mg/kg ABT-199, or both drugs. **j** Tumor volume was measured every 2 days. **k** Images of mice (*n* = 3) from each group are presented to show the sizes of the tumors. **l** Tumors were excised from the animals and weighed. **m** Representative H&E staining and immunohistochemical staining of c-Myc, BCL-2, Ki67, and cleaved caspase-3 in tumor sections (original magnification × 400). Data are shown as means ± SEM. \**p* \< 0.05, \*\**p* \< 0.01, and \*\*\*\**p* \< 0.0001

In order to reveal the mechanism by which the YL064 induces cytotoxicity in DLBCL cells, two representative DLBCL cell lines OCI-Ly3 and SU-DHL-2 were treated with YL064 for 6 h and subjected to RNA-Seq analysis. Interestingly, heatmaps showed that genes associated with c-Myc targets were dramatically downregulated (Fig. [1b](#Fig1){ref-type="fig"} and Supplementary Fig. [S3a](#MOESM1){ref-type="media"}). Gene set enrichment analysis (GSEA) also uncovered that genes related to c-Myc targets were significantly decreased in YL064-treated cells (Supplementary Fig. [S3b](#MOESM1){ref-type="media"}). To investigate the role of c-Myc in the anti-DLBCL effect of YL064, we transiently overexpressed c-Myc in OCI-Ly3 and SU-DHL-2 cells (Supplementary Fig. [S3c](#MOESM1){ref-type="media"}). As illustrated in Supplementary Fig. [S3d, e](#MOESM1){ref-type="media"}, the overexpression of c-Myc could partially antagonize the anti-proliferative and apoptosis-inducing effects of YL064 treatment. Moreover, the MYC transcriptional expression levels in tested DLBCL cell lines were found to be positively correlated with their susceptibilities to YL064 (Supplementary Fig. [S4](#MOESM1){ref-type="media"}). These results indicate that c-Myc is involved in the anti-DLBCL effect of YL064.

Based on the fact that c-Myc plays an important role in YL064-mediated growth inhibition of DLBCL cells, we next sought to determine the effect of YL064 on the expression of c-Myc. YL064 markedly reduced the protein levels of c-Myc in OCI-Ly3 and SU-DHL-2 cells in a dose- and time-dependent manner (Fig. [1c](#Fig1){ref-type="fig"} and Supplementary Fig. [S5a](#MOESM1){ref-type="media"}), while sinomenine did not induce a similar effect (Supplementary Fig. [S5b](#MOESM1){ref-type="media"}). Moreover, MYC and MAX mRNA levels were not obviously changed following YL064 treatment (Supplementary Fig. [S5d](#MOESM1){ref-type="media"}), indicating that the reduction of c-Myc protein occurs at the post-transcriptional level. Interestingly, the presence of a proteasome inhibitor MG132, rather than lysosome inhibitor chloroquine (CQ), prevented the YL064-induced c-Myc degradation (Fig. [1d](#Fig1){ref-type="fig"} and Supplementary Fig. [S5c](#MOESM1){ref-type="media"}). Moreover, YL064 treatment shortened the half-life of c-Myc protein (Supplementary Fig. [S5e](#MOESM1){ref-type="media"}). To further confirm that YL064 induces c-Myc degradation through the ubiquitin-proteasome system, we transfected HEK293T cells with plasmids encoding Flag-c-Myc and found that the ubiquitination level of c-Myc increased after YL064 treatment (Supplementary Fig. [S5f](#MOESM1){ref-type="media"}). In addition, YL064 treatment selectively increased c-Myc threonine 58 (T58) phosphorylation, but not that of serine 62 (S62) (Supplementary Fig. [S5g](#MOESM1){ref-type="media"}), indicating the involvement of c-Myc phosphorylation in YL064-mediated c-Myc degradation. Furthermore, the addition of MLN4924, an indirect inhibitor of cullin-RING E3 ligases by blocking cullin neddylation, blocked the degradation of c-Myc mediated by YL064 in OCI-Ly3 and SU-DHL-2 cells (Supplementary Fig. [S6](#MOESM1){ref-type="media"}). These results suggest that YL064 induces ubiquitin-proteasome-dependent degradation of c-Myc in DLBCL cells.

To uncover the molecular basis for the inhibition of c-Myc by YL064, we sought to verify whether c-Myc protein is a cellular target of YL064. For this purpose, cellular thermal shift assay (CETSA), a newly developed approach based on the thermal stabilization of ligand-bound proteins, was performed on OCI-Ly3 and SU-DHL-2 cells. Compared with the DMSO-treated group, YL064 treatment markedly decreased the thermal stability of c-Myc protein at different temperatures (Fig. [1e](#Fig1){ref-type="fig"}, upper panel and Supplementary Fig. [S7a](#MOESM1){ref-type="media"}). Furthermore, the thermal stability of c-Myc protein was tapered by YL064 in a dose-dependent manner (Fig. [1e](#Fig1){ref-type="fig"}, lower panel and Supplementary Fig. [S7b](#MOESM1){ref-type="media"}). These data indicate that YL064 may interact directly with c-Myc in cells. To further confirm this hypothesis, biotin-labeled YL064 was used to conduct the pull-down assay. As depicted in Fig. [1f](#Fig1){ref-type="fig"}, biotin-YL064 effectively pulled down c-Myc from the cell lysate. Immunofluorescence staining also showed that biotin-YL064 was co-localized with c-Myc in the nucleus of OCI-Ly3 cells (Fig. [1h](#Fig1){ref-type="fig"}). To further validate the direct interaction of YL064 and c-Myc, we incubated biotin-YL064 with recombinant c-Myc protein in vitro, and found that biotin-YL064 directly bound to c-Myc in a dose-dependent manner (Fig. [1g](#Fig1){ref-type="fig"}). More importantly, this interaction was competitively inhibited by ten-fold concentrations of unlabeled YL064 but not by sinomenine (Supplementary Fig. [S7c](#MOESM1){ref-type="media"}). We subsequently mapped the domains of c-Myc that might be responsible for its interaction with YL064 (Supplementary Fig. [S7d](#MOESM1){ref-type="media"}, upper panel). Using the immunoprecipitation assay, we found that the C-terminal HLH-Zip domain of c-Myc (amino acids 368--439) was crucial for interaction with YL064 (Supplementary Fig. [S7d](#MOESM1){ref-type="media"}, lower panel). These data provide compelling evidence supporting that YL064 interacts directly with c-Myc in DLBCL cells.

Since the high expressions of both c-Myc and BCL-2 contribute to a worse outcome in DHL and DEL than in other DLBCL subtypes, we hypothesized that targeting c-Myc and BCL-2 simultaneously by YL064 and ABT-199, a clinically available BCL-2 inhibitor, may be more effective in inducing cell death of DLBCL cells. A distinctly synergistic effect was observed in both DHL (OCI-Ly1 and OCI-Ly8) and DEL (OCI-Ly3 and U2932) lymphoma cell lines (Fig. [1i](#Fig1){ref-type="fig"} and Supplementary Fig. [S8a, b, d](#MOESM1){ref-type="media"}). CI values of YL064 and ABT-199 in DLBCL cells were shown in Supplementary Table [S1](#MOESM1){ref-type="media"}. Of note, a slightly synergistic or even antagonistic effect of YL064 and ABT-199 in SU-DHL-2 cells was observed (Supplementary Fig. [S8c](#MOESM1){ref-type="media"}). Therefore, we sought to examine whether YL064 affects the protein levels related to the BCL-2 family. We found that YL064 treatment reduced the protein levels of MCL-1 but had no effect on other proteins such as BIM, BAX, and BCL-xL (Supplementary Fig. [S9](#MOESM1){ref-type="media"}). Interestingly, YL064 treatment decreased BCL-2 protein levels in SU-DHL-2 but not in OCI-Ly3 cells (Supplementary Fig. [S9](#MOESM1){ref-type="media"}). The removal of ABT-199 target may explain why the synergistic effect is not obvious in SU-DHL-2 cells. Next, we also examined whether the co-treatment of YL064 and ABT-199 could enhance YL064-induced growth inhibition or apoptosis in OCI-Ly3 cells. As expected, ABT-199 enhanced the cytotoxicity of YL064 (Supplementary Fig. [S8e](#MOESM1){ref-type="media"}). Moreover, in OCI-Ly3 cells, the ratio of Annexin V positive cells was significantly increased after treated with YL064 plus ABT-199 compared with the groups treated with a single drug (Supplementary Fig. [S8f](#MOESM1){ref-type="media"}). Taken together, these observations set the stage for the potential therapeutic application of YL064 in combination with ABT-199.

Consistent with our previous studies,^[@CR5]^ YL064 also inhibited the phosphorylation of STAT3 on Tyr705 in DLBCL cells without affecting the total level of STAT3 (Supplementary Fig. [S10a](#MOESM1){ref-type="media"}). Heatmaps showed that genes associated with the STAT3 targets were dramatically downregulated (Supplementary Fig. [S10b](#MOESM1){ref-type="media"}). In order to evaluate the effect of STAT3 on the combined effect of YL064 and ABT-199, we used a selective STAT3 inhibitor, Stattic, to treat DLBCL cells. Stattic markedly inhibited the phosphorylation of STAT3 on Tyr705 and suppressed the proliferation of OCI-Ly3 cells (Supplementary Fig. [S10d, e](#MOESM1){ref-type="media"}). Although Stattic could enhance the effect of ABT-199 to some degree, no synergistic anti-proliferative effect was obtained in OCI-Ly3 cells (Supplementary Fig. [S10f](#MOESM1){ref-type="media"}). These results indicate that the inhibition of STAT3 may not play a key role in the combination effect of YL064 and ABT-199. We further compared the target genes of c-Myc and STAT3 in the downregulated genes of RNA-Seq data (Supplementary Fig. [S10c](#MOESM1){ref-type="media"}). Since the combination of STAT3 inhibitor with ABT-199 has no synergistic effect on DLBCL cells, we proposed that the c-Myc specific target genes may play an essential role in the combination effect of YL064 plus ABT-199 (Supplementary Table [S2](#MOESM1){ref-type="media"}).

In order to test the synergistic effect of YL064/ABT-199 combination towards high-risk DLBCLs in vivo, we chose OCI-Ly3 as a model of DEL lymphoma and OCI-Ly8 as a model of DHL lymphoma, respectively. NCG mice bearing subcutaneous xenografts of OCI-Ly3 cells were randomly divided into four treatment groups to receive YL064 (30 mg/kg), ABT-199 (50 mg/kg), their combination, or the corresponding vehicle. The results showed a reduction in tumor volumes in mice with combined treatment, as compared with YL064 or ABT-199 treatment alone (Fig. [1j](#Fig1){ref-type="fig"}). At the end of the treatment, the mice from each group were sacrificed, whose tumors were removed, photographed, and weighed. As displayed in Fig. [1k, l](#Fig1){ref-type="fig"}, the tumor size and tumor weight of the combination-treated group were lower than those of the other groups. Furthermore, the immunohistochemical (IHC) analysis revealed a markedly decrease in the cell proliferation marker Ki67, while the cell apoptosis marker cleaved caspase-3 was increased in the combination-treated tumors (Fig. [1m](#Fig1){ref-type="fig"}). More importantly, we also observed prominent downregulation of c-Myc after co-treatment, whereas BCL-2 was not changed (Fig. [1m](#Fig1){ref-type="fig"}). Similar results were obtained in the OCI-Ly8 xenograft model (Supplementary Fig. [S11](#MOESM1){ref-type="media"}). These results suggest that YL064, in combination with ABT-199, is more effective compared with monotherapy in treating DLBCL in vivo.

In summary, our data support that YL064 is a promising compound for the treatment of DLBCL through directly targeting c-Myc for degradation. Moreover, we demonstrated the combination of a c-Myc degrader and a BCL-2 inhibitor exerts synergistic effectiveness against DLBCL. Further elucidating the interaction relationship between YL064 and c-Myc may pave the way for the development of novel c-Myc-specific degraders for the treatment of DLBCL.
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